Optimal therapeutic cancer vaccines include synthetic long peptides derived from these antigenic proteins administered with an adjuvant, as well as DNA and RNA vaccines delivered to both MHC-I and MHC-II molecules of professional antigen-presenting cells (APC), namely dendritic cells (DC), thereby promoting both CD8 and CD4 T-cell responses in patients with cancers (50, 52, 53). Here, CD8A is linked to cancer.